Skip to main content

Scisparc Ltd(SPRC-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low5.14
Day High6.57
Open:6.08
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
SciSparc’s NeuroThera-Backed Collaboration Spurs New Depression Therapy Patent Filing
Tipranks
SciSparc Subsidiary NeuroThera to Take Majority Stake in Quantum Trials Firm CliniQuantum
Tipranks
SciSparc announces 1-for-9 reverse share split
Tipranks
SciSparc to Enact 1-for-9 Reverse Share Split as Outstanding Shares Shrink
Tipranks
SciSparc Amends $10 Million Note Deal, Issues $2 Million Initial Convertible Note
Tipranks
SciSparc Sets Up $10 Million Convertible Note Facility With Warrants
Tipranks
SciSparc Shareholders Approve February Governance Agenda
Tipranks
SciSparc Subsidiary NeuroThera Wins U.S. Patent for Cannabinoid-Based Antimicrobial Resistance Platform
Tipranks
SciSparc Closes Acquisition of Xylo GERD Device IP, Moves to Immediate Commercialization
Tipranks
SciSparc Launches $766,170 Registered Direct Share Offering
Tipranks
SciSparc Receives Nasdaq Notice Over Minimum Stockholders’ Equity Non-Compliance
Tipranks
SciSparc Calls February 2026 Meeting to Approve New Deloitte Auditor and Executive Equity Awards
Tipranks
SciSparc’s NeuroThera Labs Eyes Quantum Leap with New Acquisition
Tipranks
SciSparc Ltd. Announces $2.2 Million Securities Offering
Tipranks
SciSparc Announces New Patent Filing for Depression Treatment
Tipranks
SciSparc Ltd. Releases Interim Financial Results for H1 2025
Tipranks
SciSparc’s SCI-110 Study: A Potential Game-Changer for Tourette Syndrome
Tipranks
SciSparc’s Promising Clinical Study on SCI-210 for Autism Spectrum Disorder
Tipranks
SciSparc Completes Acquisition of Neurothera Labs Inc.
Tipranks
SciSparc Completes Sale of MitoCareX to N2OFF, Enhancing Cancer Drug Discovery
Tipranks
SciSparc and Clearmind’s New Patent Targets Binge Behavior Disorders
Tipranks
SciSparc Ltd. Finalizes Agreement with Miza III Ventures for Asset Transfer
Tipranks
SciSparc Ltd. Terminates Merger Agreement with AutoMax Motors
Tipranks
SciSparc’s MitoCareX Merger with N2OFF Approved by Shareholders
Tipranks
SciSparc Ltd. Announces Warrant Exercise Agreement
Tipranks
SciSparc Announces Leadership Changes and Launches Quantum Computing Initiative
Tipranks
SciSparc Ltd. Faces Merger Uncertainty with AutoMax
AllPennyStocks.com
Merger Uncertainty Sends Penny Stock Into Overdrive
Merger Uncertainty Sends Penny Stock Into Overdrive
Tipranks
SciSparc Ltd. Reports AutoMax Investigation by Israeli Authorities
Tipranks
SciSparc Ltd. Converts Debentures into Equity, Issuing New Shares
Tipranks
SciSparc Shareholders Approve Merger with AutoMax
Tipranks
SciSparc Shareholders Approve Key Proposals at August Meeting

Profile

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company. It focuses on the development of therapies to treat disorders of the central nervous system. The company's product pipeline includes SCI-110, SCI-160 and SCI-210. SciSparc Ltd. is based in TEL AVIV, Israel.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.